ADVATE is infused directly into the bloodstream, allowing the body’s blood clotting process to properly function, by temporarily raising the level of factor VIII.
With the approval in China, ADVATE is now approved in 54 countries worldwide, the company said.
Baxter BioScience business president Ludwig Hantson said, ”The approval of ADVATE in China marks an important milestone for Baxter and supports our ongoing commitment to treating individuals living with hemophilia."
ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] was initially approved by the FDA in July 2003 for control and prevention of bleeding episodes in adults and children (0-16 years) with hemophilia A.